<DOC>
	<DOCNO>NCT00725036</DOCNO>
	<brief_summary>This trial conduct Oceania . The aim trial compare safety use pulmonary inhaled human insulin s.c. insulin aspart combine NPH insulin subject type 1 diabetes .</brief_summary>
	<brief_title>Long Term Safety Trial Compare Insulin Treatment With Preprandial Inhaled Human Insulin s.c. Insulin Aspart Both Combined With NPH Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes Current treatment insulin regimen Body mass index ( BMI ) 38.0 kg/m2 HbA1c equal 13.0 % Total daily insulin dosage 100 IU/day Current acute chronic pulmonary disease ( exclude asthma ) Recurrent major hypoglycaemia Proliferative retinopathy maculopathy require acute treatment Smoker Chest Xray clinically significant abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>